A cardiovascular benefit of ophthalmic beta-blockade.
Easton
P J
PJ
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D015784:Betaxolol / Q000009:adverse effects* / Q000493:pharmacokinetics; D001682:Biological Availability; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D009883:Ophthalmic Solutions; D013575:Syncope / Q000209:etiology*; D013999:Timolol / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D013999:Timolol; D015784:Betaxolol